Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy - Archive ouverte HAL Access content directly
Journal Articles Sleep Medicine Year : 2022

Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy

(1) , (2) , (3, 4) , (5) , (6) , (7, 8) , (9, 10) , (11) , (11) , (11) , (12)
1
2
3
4
5
6
7
8
9
10
11
12

Abstract

Objectives: This analysis characterized changes in weight in participants with obstructive sleep apnea (OSA) or narcolepsy treated with solriamfetol (Sunosi™) 37.5 (OSA only), 75, 150, or 300 mg/d. Methods: In two 12-week, randomized, placebo-controlled trials and one 1-year open-label extension study, changes in weight were evaluated from baseline to end of study (week 12 or week 40 of the open-label extension [after up to 52 weeks of solriamfetol treatment]) in participants with OSA or narcolepsy. Results: After 12 weeks of solriamfetol treatment, median percent change in weight from baseline across all solriamfetol doses was -0.84%, compared with 0.54% for placebo, in participants with OSA; and -0.07%, compared with 3.08% for placebo, in participants with narcolepsy. After up to 52 weeks of solriamfetol treatment, overall median percent change in weight from baseline was -1.76%, which showed a dose-dependent pattern (75 mg, 0.57%; 150 mg, -1.2%; 300 mg, -2.5%). Results were similar in subgroups of participants with OSA or narcolepsy, with overall median percent changes in weight of -2.2% and -1.1%, respectively. After up to 52 weeks of solriamfetol treatment, the percentage of participants with weight loss ≥5% relative to baseline was 25.7% overall and increased in a dose-dependent manner (75 mg, 4.5%; 150 mg, 17.3%; 300 mg, 32.4%). Results were similar among subgroups of participants with OSA or narcolepsy, with 26.4% and 24.2% of participants experiencing weight loss ≥5%, respectively. No weight-related treatment-emergent adverse events were serious. Conclusions: Solriamfetol treatment was associated with decreases in body weight in a dose-related manner.
Fichier principal
Vignette du fichier
1-s2.0-S1389945722011005-main.pdf (1.28 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03793913 , version 1 (02-10-2022)

Identifiers

Cite

Atul Malhotra, Patrick Strollo, Jean-Louis Pépin, Pierre Schweitzer, Joris Lammers, et al.. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy. Sleep Medicine, 2022, 100, pp.165-173. ⟨10.1016/j.sleep.2022.08.005⟩. ⟨inserm-03793913⟩

Collections

INSERM UGA
2 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More